Competition from ALNY: ALN-RSV01 interim analysis by ye2011 and study data 2012. Program is partnered with CBST. not too sure about market potential or data; only briefly glanced.
The existing clinical data for ALN-RSV01 hasn't been too impressive I don't believe so I don't know how concerned I am about this potential threat. (I do still find ALNY interesting for the rest of their pipeline and the valuation so I keep an eye on them.)
Market Data 
Markets 
AI
